A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
NCT ID: NCT06742281
Last Updated: 2025-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
432 participants
INTERVENTIONAL
2024-12-05
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
NCT05736835
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
NCT04563702
Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19
NCT04619628
Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers
NCT05522335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Number of Participants:
The proposed enrollment for this study is approximately 434 participants, that includes 16 participants enrolled in Sentinel Cohort 1 and Sentinel Cohort 2 (8 participants in each cohort).
Treatment Assignment:
Participants in Sentinel Cohort 1 and Sentinel Cohort 2 will be assigned to receive a single dose of CVXGA (CVXGA50) intranasally and will not receive an IM placebo.
All other participants in the study will be randomized 1:1 to receive a single dose of CVXGA (CVXGA50) intranasally (plus a single dose of IM placebo), or a single dose of IM COMIRNATY (plus a single dose of intranasal placebo).
Study visits: Participants will be asked to complete approximately 6-7 clinic visits, over a period of approximately 12 months duration per participant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CVXGA (CVXGA50)
CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
CVXGA (CVXGA50)
CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
COMIRNATY®
COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
COMIRNATY®
COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COMIRNATY®
COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
CVXGA (CVXGA50)
CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has completed any WHO/FDA-authorized or approved primary COVID-19 vaccination series.
* Has received last COVID-19 vaccine no less than 6 months prior to study enrollment (study vaccination).
* If a female of childbearing potential who is sexually active, agrees to use an adequate method of birth control from Screening through 90 days after last study vaccination, and has used an adequate birth control method for at least 30 days prior to Screening.
A. Female of childbearing potential is defined as post onset menarche and pre-menopausal person capable of becoming pregnant. This does not include females who meet any of the following conditions: a) menopausal \>2 years; b) tubal ligation \>1 year; c) bilateral salpingo-oophorectomy; or d) hysterectomy.
B. Adequate contraception is defined as a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label. Examples include: oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; the female participant has exclusively female sexual partners; partner is sterile or otherwise unable to produce sperm (information on the person's sterility can come from the site personnel's review of the participant's medical records or interview with the participant regarding her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); or male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
* Is medically stable, as determined by the site investigator (based on review of health status, vital signs, medical history, and physical examination).
* Agrees to not participate in any other SARS-CoV-2 infection prevention trial (vaccine, drug, biologic, or pre-exposure prophylaxis \[PrEP\]) during participation in the study.
* Willing and able to provide informed consent prior to initiation of study procedures.
* Is available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study.
Exclusion Criteria
(a. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol.)
* Has had a positive COVID-19 test within the 90 days prior to Screening or study vaccination.
* Current or planned participation in any other interventional clinical trial.
* Prior receipt of a PIV5-based vaccine (e.g., CVXGA1, CVXGA35, or BLB201 \[an RSV vaccine being developed by CyanVac/Blue Lake Biotechnology\]).
* Participation in research involving any investigational product within 45 days prior to Screening or study vaccination.
* Receipt of any approved or authorized products intended to prevent SARS-CoV-2 infection within 6 months prior to Screening (complete list provided in the pharmacy manual).
* Receipt or anticipated receipt of, within 7 days prior through 31 days after study vaccination, any intranasal medication including FDA approved prescription or over-the-counter products or non-FDA approved alternative medicine products (e.g., intranasal Fluticasone {commonly used intranasal products that would be used, which is not herbal/naturopathic}, Ayurvedic oil or other naturopathic substances).
* Anticipated use of nasal irrigation (e.g., Neti PotTM) from Screening through 31 days after study vaccination.
* Receipt of blood products or immunoglobulins within 60 days prior to Screening or study vaccination.
* Received influenza vaccination within 14 days prior to Screening or study vaccination, or any other vaccine within 30 days prior to Screening or study vaccination.
* Any significant or uncontrolled autoimmune, immunodeficiency disease/condition, or autoinflammatory disorder (e.g. untreated or advanced human immunodeficiency virus \[HIV\] infection with CD4 counts \<200 cells/mm3, history of acquired immunodeficiency syndrome \[AIDS\] defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV).
* Unstable illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to Screening or study vaccination.
* History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or presence of any medical condition that, in the opinion of the investigator, increases risk of myocarditis or pericarditis.
* Administration of immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs within the following timeframes:
1. B-cell therapies within the 6 months prior to Screening or study vaccination.
2. Prednisone, ≥20 mg for more than 2 weeks, within the 30 days prior to Screening or study vaccination.
3. Monoclonal antibodies that may suppress aspects of immune response (e.g., Dupixent) within the 6 months prior to Screening or study vaccination.
4. Other medications in this category, including but not limited to high-dose inhaled corticosteroids (\>800 mcg/day of beclomethasone dipropionate or equivalent); antimetabolites; transplant immunosuppressive agents; alkylating agents; cell-depleting agents; or cancer chemotherapeutics, within the 90 days prior to Screening or study vaccination.
5. Any medication for any period of time that, in the opinion of the site investigator, could impede immune response to vaccination.
* Individuals who have close contact or high-risk contact with persons who may be severely immunocompromised, within 14 days following the study vaccination. High-risk contacts include but are not limited to:
1. Residents of nursing homes or rehabilitation facilities
2. Persons of any age with any significant immunodeficiency disease (e.g., untreated or advanced HIV, history of AIDS, or clinical manifestations of HIV)
3. Persons of any age being administered immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs
4. Persons of any age with a known history of significant airway reactivity to viruses (e.g., severe asthma, advanced chronic obstructive disease, or cystic fibrosis)
5. Persons of any age immunosuppressed due to cancer or undergoing active treatment for cancer
6. Women who are pregnant, breastfeeding, or who plan to become pregnant during the study; and
7. Infants age ≤6 months.
* Known contraindication to IM injection (e.g., bleeding diathesis, acquired coagulopathy) or to intranasal administration (e.g., severe nasal obstruction, significant chronic rhinitis, nasal septal defect causing significant breathing problems, unrepaired cleft palate, nasal polyps, or other nasal abnormality that, in the opinion of the investigator, may affect vaccine administration).
* History of significant/severe wheezing or respiratory symptoms resulting in hospitalization or known bronchial hyperreactivity to viruses.
* History of severe adverse reaction to vaccination in the past, including to COVID-19 vaccination.
* Any known allergies to components contained in CVXGA or COMIRNATY (including polyethylene glycol \[PEG\] allergies), or latex.
* Women who are pregnant, breastfeeding, or who plan to become pregnant during the study.
* Any other condition that, in the opinion of the site investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results.
* Study team member or first-degree relative of any study team member (inclusive of CyanVac and site personnel involved in the study).
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biomedical Advanced Research and Development Authority
FED
CyanVac LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Jin
Role: PRINCIPAL_INVESTIGATOR
CyanVac LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pinnacle Research Group, LLC
Anniston, Alabama, United States
Velocity Clinical Research, Phoenix
Phoenix, Arizona, United States
Velocity Clinical Research, Chula Vista
Chula Vista, California, United States
Velocity Clinical Research, San Diego
La Mesa, California, United States
Imax Clinical Trials
La Palma, California, United States
Artemis Institute for Clinical Research
Riverside, California, United States
Clinical Innovations Inc. dba CITrials
Riverside, California, United States
Avacare
Sacramento, California, United States
Collaborative Neuroscience Research, LLC
Torrance, California, United States
Velocity Clinical Research, Washington DC
Washington D.C., District of Columbia, United States
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida, United States
Homestead Associates in Research, Inc
Homestead, Florida, United States
Biscayne Clinical Research
North Miami Beach, Florida, United States
Headlands Research Orlando
Orlando, Florida, United States
Best Choice Medical and Research Service
Pembroke Pines, Florida, United States
Forcare Clinical Research
Tampa, Florida, United States
Guardian Angel Research Center
Tampa, Florida, United States
Lifeline Primary Care/Avacare
Lilburn, Georgia, United States
Velocity Clinical Research, Savannah
Savannah, Georgia, United States
Clinical Research Atlanta
Stockbridge, Georgia, United States
Velocity Clinical Research, Boise
Meridian, Idaho, United States
Velocity Clinical Research, Sioux City
Sioux City, Iowa, United States
Velocity Clinical Research, Covington
Covington, Louisiana, United States
Velocity Clinical Research, Lafayette
Lafayette, Louisiana, United States
Velocity Clinical Research, New Orleans
New Orleans, Louisiana, United States
CBH Health
Gaithersburg, Maryland, United States
Advanced Primary and Geriatric Care/Avacare
Rockville, Maryland, United States
Velocity Clinical Research, Rockville
Rockville, Maryland, United States
DM Clinical Research
Southfield, Michigan, United States
Velocity Clinical Research - Norfolk
Norfolk, Nebraska, United States
Quality Clinical Research, Inc
Omaha, Nebraska, United States
Velocity Clinical Research, Omaha
Omaha, Nebraska, United States
DM Clinical Research
Jersey City, New Jersey, United States
Velocity Clinical Research, Binghamton
Binghamton, New York, United States
Rochester Clinical Research
Rochester, New York, United States
Trial Management Associates, LLC
Wilmington, North Carolina, United States
Velocity Clinical Research, Cleveland
Beachwood, Ohio, United States
Velocity Clinical Research, Mt. Auburn
Cincinnati, Ohio, United States
Velocity Clinical Research, Springdale
Cincinnati, Ohio, United States
Tekton Research, LLC
Yukon, Oklahoma, United States
DM Clinical Research
Philadelphia, Pennsylvania, United States
Velocity Clinical Research, Anderson
Anderson, South Carolina, United States
Velocity Clinical Research Gaffney
Gaffney, South Carolina, United States
Avacare
Austin, Texas, United States
Tekton Research, LLC
Austin, Texas, United States
Velocity Clinical Research, Austin
Austin, Texas, United States
Pan American Clinical Research, LLC
Brownsville, Texas, United States
Avacare
Fort Worth, Texas, United States
DM Clinical Research
Houston, Texas, United States
DM Clinical Research
Houston, Texas, United States
Avacare
San Angelo, Texas, United States
Tekton Research, LLC
San Antonio, Texas, United States
Velocity Clinical Research, Salt Lake City
West Jordan, Utah, United States
Clinical Research Partners LLC
Richmond, Virginia, United States
Velocity Clinical Research, Suffolk
Suffolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CVXGA-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.